Close Menu

USPTO

The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.

The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.

The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.

Split?

Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.

The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.

Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.

The University of California is appealing the recent CRISPR/Cas9 patent decision.

The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.

Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.

The First Call

The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.